At least 10% of adults and nearly all children who receive renal-replacement therapy have an inherited kidney disease. These patients rarely die when their disease progresses and can remain alive for many years because of advances in organ-replacement therapy. However, these disorders substantially decrease their quality of life and have a large eff ect on health-care systems. Since the kidneys regulate essential homoeostatic processes, inherited kidney disorders have multisystem complications, which add to the usual challenges for rare disorders. In this review, we discuss the nature of rare inherited kidney diseases, the challenges they pose, and opportunities from technological advances, which are well suited to target the kidney. Mechanistic insights from rare disorders are relevant for common disorders such as hypertension, kidney stones, cardiovascular disease, and progression of chronic kidney disease.
Introduction
In the USA a rare disease is defi ned as a disease that aff ects fewer than 200 000 people in the country, whereas this designation is given to diseases that aff ect fewer than one in 2000 people in Europe, 1 fewer than one in 2500 people in Japan, 2 and fewer than one in 500 000 people in China. 3 Rare diseases are often categorised as orphan diseases to stress their severity, insuffi cient resources and knowledge available, and the specifi c conditions to develop or make drugs for them. They represent a group of 6000 to 8000 highly heterogeneous disorders that aff ect roughly 30 million patients in Europe. 1 About 80% of rare diseases have an identifi ed genetic origin. The incidence of a rare disease can vary substantially between regions or ethnic groups. For example, congenital nephrotic syndrome of the Finnish type occurs more frequently in Finland (incidence of one in 8200 people) than in other parts of the world.
Rare kidney diseases constitute at least 150 diff erent disorders and they have an overall prevalence of about 60-80 cases per 100 000 in Europe and the USA. [4] [5] [6] At least 10% of adults and nearly all children who progress to renal-replacement therapy have an inherited kidney disease, the fi fth most common cause of end-stage renal disease after diabetes, hypertension, glomeru lonephritis, and pyelonephritis. Because of progress in renalreplacement therapy, patients with inherited kidney disorders rarely die when their disease progresses and can live for many years. However, these patients often have compromised health with a poor quality of life. For instance, children with severe congenital nephropathies, who can be dialysed from neonatal age onwards, face many decades of life with end-stage renal disease and have a high likelihood of changes in physical, cognitive, and psychosocial development. Inherited kidney disorders have multisystem complications that add to the typical challenges for rare disorders-ie, variable phenotypes, fragmented clinical and biological data, an absence of standardisation for diagnostic procedures, and poor knowledge for disease mechanisms and natural history. 7 In this review, we discuss the epidemiology, range, and specifi c nature of rare inherited kidney diseases of genetic origin and note challenges that arise in their management. We then address opportunities from technological advances and high-throughput screening approaches, which are particularly well suited to target the kidney. We particularly focus on the link between these technologies and the innovative clinical research programmes and initiatives. We show how these collaborative studies could aff ect the clinical management of rare kidney diseases and beyond, with mention of insights about eff ects of sex and ageing, the progression of chronic kidney disease, and understanding for more common disorders.
Rare inherited kidney diseases: why they are diff erent
The kidney is a complex organ, composed of many specialised cell types, with highly regulated functions that are essential for homoeostasis. 8 The kidneys are exposed to and aff ect the extracellular environment more than any other organ-regulating water and electrolyte balance, acid-base homoeostasis, tissue oxygen supply, hormone and vitamin metabolism, and innate and adaptive immunity. The kidneys are also essential for metabolic clearance and secretion of drug metabolites. These functions have large quantitative eff ects that can directly aff ect body composition. Primary kidney disorders can substantially aff ect blood pressure, plasma composition, electrolyte and acid-base homoeostasis, cardiac excitability, growth dynamics and puberty, and CNS and cognitive functions. Various aspects of renal function can also be aff ected in extrarenal rare disorders or polymalformative syndromes, including mitochondrial cytopathies. [9] [10] [11] [12] Genetics were fi rst used in nephrology in the 1980s with the mapping of autosomal dominant polycystic kidney disease in 1985 13 and the fi rst identifi cation of a causal mutation for a monogenic kidney disorder (Alport's syndrome) in 1990.
14 These breakthroughs were followed by identifi cation of genes involved in classic disorders such as nephrogenic diabetes insipidus, 15 autosomal dominant polycystic kidney disease type 1, 16 Liddle's syndrome, 17 Dent's disease, 18 Bartter's and Gitelman's syndromes, 19, 20 nephropathic cystinosis, 21 and
Panel: Milestones in research of inherited kidney diseases

Milestones in nephrogenetics
1985 Mapping the fi rst gene location for an inherited kidney disorder (autosomal dominant polycystic kidney disease, on chromosome 16) 13 1990 First detection of a point mutation at a specifi c locus single-gene disorder, COL4A5 14 1992 Molecular basis of nephrogenic diabetes insipidus described 15 1993 Identifi cation of the tuberous sclerosis gene (TSC2) 1994 Cloning of the PKD1 gene, responsible for about 85% of autosomal dominant polycystic kidney disease cases; challenging due to the size (46 exons) and complex organisation (presence of six highly homologous sequences of exons 1-33) of the gene on chromosome 16p13·3 16 1994 Liddle's syndrome reported to be due to activating mutation of the sodium channel ENaC 17 1996 Molecular basis for inherited kidney stone diseases identifi ed 18 1996 Molecular basis of Bartter's and Gitelman's syndromes described 19, 20 22 With the increased use of high-throughput and next-generation sequencing technologies, investigators have now defi ned the genetic basis of more than 160 rare kidney diseases (table 1, table 2 ). These disorders are caused by mutations in genes coding for a wide range of proteins including receptors, channels and transporters, enzymes, transcription factors, and structural components that might also have a role in extrarenal organs (bone, eye, brain, skin, etc). Figure 1 shows rare inherited disorders of the kidney. In addition to monogenic diseases, the combination of variants in the same genes or in genes involved in common pathways that operate in the kidney might cause variable eff ect sizes that cannot be explained by conventional genotypephenotype correlations. 8, 28 Careful phenotype assessments of recessively inherited kidney disorders have substantiated the eff ect of carrier states. For example, Gitelman's syndrome is caused by loss-of-function mutations in SLC12A3, which encodes the thiazidesensitive sodium-chloride cotransporter in the distal convoluted tubule. About 1% of the general population are heterozygous carriers of SLC12A3 mutations; such carriers have a lower blood pressure and a lower risk of hypertension than have the general population. 
Specifi c challenges Unknown genetic cause
Despite progress in understanding of molecular causes of rare kidney diseases, the pathways for most inherited nephropathies still need identifi cation. Known monogenic causes explain only 30-40% of cases of familial steroidresistant nephrotic syndrome, 40-50% of cases of congenital tubulopathy, and 50-60% of cases of atypical haemolytic uraemic syndrome. Poor appreciation of genetic studies by health-care providers is of concern. Even for well defi ned disorders such as Alport's, Bartter's, and Gitelman's syndromes, use of genetic testing remains rare, mainly because of high cost and long turnaround times for conventional genetic screening, the preconception that a genetic diagnosis will not aff ect clinical management, insuffi cient genetic literacy, and diff erences in access to genetic testing and insurance coverage.
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Absence of biomarkers
Even though routine analysis of urine samples can be helpful to indicate the origin of some disorders (fi gure 1), the assessment of kidney disease activity and progression is still mainly based on crude markers such as serum creatinine and proteinuria. The descriptive assessment of kidney biopsy specimens with use of light and electron microscopy, supplemented by a small set of immunological marker proteins, is still the diagnostic gold standard.
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Clinical heterogeneity
Many rare mendelian kidney diseases have a diff erent prevalence in diff erent populations and have substantial clinical heterogeneity in presence, age of onset, severity, and progression of symptoms. Diff erent incidence rates in populations lend support to a role for genetics, and potentially the environment, in the pathogenesis of disease. Phenotypical diff erences can be the result of genetic (locus) heterogeneity-eg, in Bartter's syndrome, mutations in SLC12A1 or KCNJ1 are associated with a severe neonatal onset of disease, whereas mutations in CLCNKB usually result in milder and later-onset disease symptoms and mutations in BSND cause Bartter's syndrome plus sensorineural deafness. 33 Allelic heterogeneity might also explain disease variability. For instance, in autosomal recessive polycystic kidney disease, the presence of two truncating mutations in the disease gene, PKHD1, is associated with a lethal disease; at least one missense mutation is necessary for survival after neonatal age. However, the absence of two truncating mutations cannot be regarded as synonymous with a favourable prognosis. 34 Therefore, prediction of the clinical outcome for children with autosomal recessive polycystic kidney disease with one or two missense mutations remains diffi cult. In 2014, Tory and colleagues 25 described mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. In most rare inherited kidney diseases, the mutational diversity is large and genotype-phenotype correlations are loose or absent, showing the insuffi cient study populations sizes and poor access to genetic testing.
Eff ects of modifi er genes, epigenetic changes, or other modifying factors also contribute to intrafamilial variability. Sex might modify the phenotype, as it does in Gitelman's syndrome. 35 Oligogenic modifi er eff ects, by which a second gene can modify the action of a dominant gene, play a part in genetic ciliary diseases such as nephronophthisis. For instance, in patients with homozygous NPHP1 deletions, the presence of an additional heterozygous NPHP6 or NPHP8 mutation might cause additional eye or cerebellar involvement. 36, 37 However evidence is in early stages for genetic and epigenetic modifi ers in rare inherited kidney diseases.
Insuffi cient ontology
An increasing number of rare kidney diseases that were previously considered to be single disorders have been shown to be aetiologically heterogeneous. Diff erent abnormalities can aff ect the same biological pathways and give rise to similar clinical, biochemical, and histopathological features. The imperfect prognostic value of traditional diagnostic nomenclatures is largely explained by its inability to diff erentiate underlying disease mechanisms. For instance, membranoproliferative glomerulonephritis can be caused by glomerular deposition of circulating immunoglobulins or immune complexes, by mutations in complement proteins regulating C3 convertase, and by acquired autoantibodies directed against these proteins or C3 itself. 38 Another example of heterogeneity is the generalised dysfunction of the proximal tubule (renal Fanconi's syndrome). 39 Emerging disease ontologies based on molecular pathophysiology will need prognostic validation with long-term outcomes.
Carrier state
Information on an individual's carrier status for a genetic renal disorder is not only important for genetic counselling, but might also have clinical implications for the carriers themselves. Heterozygous carriers of X-chromosome-linked disorders are usually asymptomatic or mildly aff ected, but in some heterozygotes, a severe disease outcome is noted. Disease severity in women with X-linked renal disorders such as Alport's syndrome and Fabry's disease is not related to the genotype, and is most probably a result of skewed X-chromosome inactivation. Therefore, women carrying an X-chromosome-linked Alport's syndrome mutation (COL4A5 mutation), should be considered at risk to develop disease and be observed similarly to men to assess for early signs or progression to renal insuffi ciency. Likewise, women carrying heterozygous GLA mutations can be as severely aff ected by Fabry's disease as can hemizygous men, with progressive, multiorgan involvement, particularly nephropathy. Further research is needed to determine methods to predict the individual outcome for female carriers of these rare X-chromosomelinked renal disorders.
Carrier status might also have implications for livingrelated kidney transplantation. Unaff ected individuals carrying a heterozygous recessive gene mutation are theoretically expected not to develop disease. Therefore, living related transplantation is usually considered suitable from patients with rare autosomal recessive renal diseases such as podocytopathies, autosomal recessive polycystic kidney disease, cystinosis, and nephronophthisis.
However, whether unilateral nephrectomy in heterozygous individuals aff ects longterm renal function has not been determined, and studies from large registries are needed.
Insuffi cient model organisms
Knockout and transgenic mouse models are highly informative about the eff ects of genetic variation on renal phenotypes. 40 Limitations of these models include long generation time, strain eff ects, adaptation, and species diff erences in development, growth, physiology, metabolism, and adaptation to chronic kidney disease. 41, 42 These obstacles mean that mouse models are of little use for rapid testing of candidate genes arising from nextgeneration sequencing and for drug development.
Opportunities Omics technologies
Omics technologies provide great opportunity in research for rare renal diseases because they can probe the diseased organ directly (fi gure 2). Kidney biopsy samples allow investigators to study intrarenal processes ex vivo with use of transcriptomic and proteomic approaches for compartment-specifi c profi ling of mRNA transcripts and non-coding regulatory RNA species. The European Renal cDNA Bank project has provided a reference database for gene expression profi les of microdissected kidney specimens from patients with various renal disorders and from healthy individuals. 43 Urine is a non-invasive resource to study biochemical and molecular readouts directly from the kidney. Amniotic fl uid is available prenatally for studies of renal development or transport defects. 44 Exosome isolation from urine and amniotic fl uid allows study of membrane and cytoplasmatic proteins and RNAs that derive from epithelial cells facing the urinary space. Although exosome isolation remains technically challenging, studies of podocyte and cystic kidney disorders indicate great potential of this analysis in the study of hereditary kidney diseases. [45] [46] [47] The possibility that application of omics approaches to such samples could identify molecular signatures and prognostic biomarkers was suggested by fi ndings from studies in common kidney disorders such as diabetic nephropathy, 48 allograft rejection, 49 and vesicoureteral refl ux. 50 Changes in urinary miRNA profi le have been detected in disorders such as lupus nephritis 51 and renal fi brosis. 52 The study of the urine metabolome by nuclear magnetic resonance spectroscopy and mass spectrometry is another emerging technology that can generate molecular fi ngerprints of diagnostic or prognostic value, 53 as already shown in patients with Fanconi's syndrome. 54 
Next-generation sequencing
Next-generation sequencing techniques will improve diagnostic effi ciency for genetic renal diseases through simultaneous investigation of all relevant genes for a given phenotype at much reduced costs and turn-around times. 24, 55, 56 Successful application of next-generation sequencing in diagnostic mutation screening with use of multigene panels has been shown for Alport's syndrome, 57 steroid-resistant nephrotic syndrome, 58 and nephronophthisis. 59 Beyond disease-specifi c nextgeneration sequencing panels, exome sequencing (and potentially even whole-genome sequencing) will soon become part of routine molecular diagnostics, further improving diagnostic yield. Sequencing-based technologies are also increasingly applied to individual cells, with the aim to integrate genomics, transcriptomics, epigenomics, and proteomics for multilevel analysis of cellular mechanisms. These analyses will need robust single-cell isolation, a potentially challenging task for a heterogeneous tissue such as kidney. 60 The abundance of genetic and molecular information generated by next-generation sequencing poses a new challenge because bioinformatic capacities and analysis methods need development. The characterisation of candidate disease genes and individual mutations needs effi cient model systems. Innovative strategies are also needed to integrate multilevel omics information with clinical phenotypes. 61 The European Consortium for HighThroughput Research in Rare Kidney Diseases (EURenOmics) is now working on a cohesive bioinformatic platform for rare nephropathies. A renal phenome database is being created, using the Human Phenotype Ontology website. 62 The phenotype information will be linked to genomic, transcriptomic, proteomic, and metabolomic studies, omics datasets, and the public domain knowledge-base in a systems biology approach to identify molecular pathways associated with phenotypic features.
Model organisms
The mouse is still the major organism used to model rare kidney disorders. Cell-specifi c and time-specifi c genetargeting methods and RNA-based technologies can manipulate gene function, which can be paralleled by targeted embryonic stem-cell clones and large-scale mutagenesis programmes. 40 The precision and number of phenotypic traits that can be tested in mice has largely increased. 42, [63] [64] [65] Advances in rat genetics and genome editing, combined with robust phenotype analyses in more than 500 rat strains, pave the way for use of the rat as an alternative model organism for human diseases. 66, 67 By contrast with rodents, simple model organisms provide opportunity for higher-throughput gene manipulation and phenotype quantifi cation. The zebrafi sh (Danio rerio) is now routinely used for study of kidney diseases and renal regeneration, based on conserved genomic organisation and nephron structure. 68 Zebrafi sh larvae are used to investigate kidney developmental disorders and ciliopathies, 69 glomerular disorders, 70 and tubulopathies. 71 The fruit fl y (Drosophila melanogaster) nephrocyte combines fi ltration with protein reabsorption and can therefore be used as a model for podocytes and proximal tubule cells. 72, 73 Although the nematode Caenorhabditis elegans does not possess an excretory system comparable with the mammalian kidney, conserved genes involved in formation of the primary cilium, kidney fi ltration barrier, or vasopressin response do exist in this organism. 74, 75 Because few laboratories engage in such model studies, it is a challenge to integrate functional annotations into clinically relevant information.
Research programmes, cohorts, biorepositories
Fragmentation of patient-related information is a major obstacle for research into rare disease. Networks, registries, databases, and biorepositories have been created to overcome this issue. The European Platform for Rare Disease Registries provides instruments to develop exchange between individual registries, whereas the Patient Registries Initiative will promote interoperable patient registries. The RD-CONNECT platform will integrate rare disease projects devoted to next-generation sequencing and high-throughput approaches, and is linked with the International Rare Diseases Research Consortium (IRDiRC) which aims to deliver 200 new Figure 2 : Application of omics technologies in rare kidney diseases Next-generation sequencing techniques and omics technologies, which can directly probe the kidney, will improve diagnostic effi ciency for genetic renal diseases. Genomic studies and molecular profi ling of kidney tissues, plain and exosome-enriched urine, and multiscalar bioinformatic analysis of crucial disease pathways, will allow the development of mechanistic renal disease ontologies, diagnostic tests, biomarkers, and novel therapeutic targets. therapies by 2020. EURenOmics is one of the fi rst clinical research projects of IRDiRC and RD-CONNECT. It is a consortium for omics research that integrates registries and biobanks with detailed phenotype information and biomaterials from more than 13 000 patients with rare kidney diseases. These eff orts are paralleled by initiatives launched by professional and scientifi c societies. For instance, European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) has implemented a working group on inherited kidney diseases to promote research, care, and dissemination of knowledge. 76 Nationally, centres of excellence are being established by health authorities to improve health-care access and to help to transition patients from paediatric to adult care. 
Non-rare inherited kidney disorders
Rare kidney diseases exist alongside autosomal dominant polycystic kidney disease, one of the most common inherited disorders, with a prevalence of one in 1000 people (about 750 000 patients in Europe). Because of its autosomal dominant transmission and the slow progression of disease, patients with autosomal dominant polycystic kidney disease form an important pressure group that is able to drive attention to rarer inherited kidney diseases and to infl uence other organisations, as well as trends in research funding and drug development.
Opportunities for common diseases
Study of rare kidney diseases provides insights into more common disorders. The UMOD gene, in which dominantly inherited mutations can cause familial juvenile hyperuricaemic nephropathy, is an example. 23 Genome-wide association studies showed that common variants in the UMOD promoter were strongly associated with the risk of chronic kidney disease and hypertension in the general population. 78 Further studies showed the biological activity of these variants and how they cause hypertension. 79 The elucidation of this mechanism was helped by previous studies of genes that cause Bartter's syndrome. 20 Likewise, variants in the genes encoding the megalin (LRP2) and cubilin (CUBN) receptors that mediate tubular endocytosis of ultrafi ltered proteins and are defective in rare disorders were shown by genomewide association studies to aff ect renal function and risk of chronic kidney disease. 80, 81 Conversely, genome studies might incidentally point to candidate genes for rare diseases. For example, the identifi cation of CNNM2 as the causative gene for a rare genetic disorder of renal magnesium wasting was based, among other fi ndings, on the association between common variants in CNNM2 and serum Mg² + concentrations.
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Perspectives Diagnostics
The use of next-generation sequencing is expected to increase diagnostic effi ciency for rare kidney diseases. Accurate genetic counselling and carrier testing will become available for an increased number of families, with potential for early prenatal or preimplantation diagnostic testing in severe cases. A defi nite genetic diagnosis could have important prognostic value in some diseases. For instance, the effi cacy of plasmapheresis and outcome of renal transplantation in atypical haemolytic uraemic syndrome is correlated with the type of mutation in complement genes. Patients with mutations in complement genes that encode circulating proteins (CFH and CFI) have worse outcomes than have patients with mutations in MCP (CD46), encoding a cell-associated protein. 83 Likewise, genetic testing in patients with steroidresistant nephrotic syndrome helps to predict the response to immunosuppressive therapies and the risk of posttransplant disease recurrence. 84 In primary hyperoxaluria type 1, the Gly170Arg and Phe152Ile aminoacid changes caused by mutations in AGXT have been associated with responsiveness to pyridoxine supplementation. 85 As we discuss, policies to promote clinically relevant genetic testing and the adequate delivery and integration of genetic information should be implemented.
Treatment
Eff ective therapeutic approaches exist for some rare kidney diseases (panel). Genetic and mechanistic insights could improve existing therapies or help to develop new ones (fi gure 3). Cystinosis is a lysosomal storage disease Figure 3 : Examples of molecular targets in rare inherited kidney diseases (A) Cystinosis is caused by defective cystinosin, a ubiquitous lysosomal protondriven cystine transporter working in parallel with the vacuolar H+-ATPase. In patients with cystinosis, the loss of function of cystinosin causes cystine to accumulate in lysosomes (shown here in a proximal tubule cell). Cysteamine reduces the accumulation of cysteine by entering lysosomes and forming a cysteamine-cysteine complex, which resembles lysine and can be exported by PQLC2. Modifi ed from Jézégou and colleagues. 86 (B) Patients with haemolytic uraemic syndrome have uncontrolled complement activation due to defi ciency of natural complement regulatory factors. Eculizumab is a humanised monoclonal antibody that inhibits the cleavage of the complement protein C5, blocking complement activation and complement-mediated thrombotic microangiopathy in patients with haemolytic uraemic syndrome. Patients with haemolytic uraemic syndrome due to recessive mutations in DGKE, which is not associated with activation of the complement system, do not respond to eculizumab or plasma exchange. Modifi ed from Noris and colleagues. 87 (C) In the principal cells that line the collectin g ducts, stimulation of the vasopressin-2 receptor (V2R) by vasopressin leads to an increase in cAMP, causing a protein kinase A (PKA)-mediated phosphorylation of AQP2 and their insertion into the apical plasma membrane. The resulting increase in transcellular water permeability mediates concentration of urine. Most mutations in AVPR2 (X-chromosome-linked nephrogenic diabetes insipidus) and AQP2 (autosomal recessive nephrogenic diabetes insipidus) result in misfolded V2R and AQP2 mutations in the endoplasmic reticulum (class 2 mutations). Pharmacological chaperones (eg, glycerol) can rescue such class 2 mutant proteins from the endoplasmic reticulum. Cell-permeable V2R antagonists stabilise the structure of mutant V2R and allow them to exit the endoplasmic reticulum and translocate to the basolateral plasma membrane. At the membrane, vasopressin will displace the antagonist and allow restoration of the cAMP cascade. This action of V2R antagonists can depend on V2R mutation. V2R agonists function similarly and might also stimulate misfolded V2R in the endoplasmic reticulum without inducing maturation. Mutant AQP2 can be rescued from the endoplasmic reticulum by glycerol. Modifi ed from Robben and colleagues. 88 For the website of the Working Group on Inherited Kidney Diseases see http://www.era-edta.org/wgikd/ ERA-EDTA_working_group_on_ Inherited_kidney_disorders.htm caused by mutations in the CTNS gene resulting in intralysosomal accumulation of cystine crystals, which damage several organs, including kidney. 21 Oral administration of cysteamine, which reverses cystine accumulation via a newly described PQLC2 heptahelical protein (fi gure 3), 86 substantially delays renal disease progression and other complications. 89 Findings from a mouse study of cystinosis suggest that stem-cell gene therapy might also improve the multisystem complications of cystinosis. 27 The elucidation of molecular mechanisms for disease might create opportunities for drug repositioning (ie, application of known drugs to new indications). For instance, recurrence of proteinuria after kidney transplantation in some patients with focal-segmental glomerulosclerosis has been linked to an upregulation of B7-1 (CD80), a costimulatory molecule normally expressed in T-lymphocytes, which changes foot process anchoring in podocytes. 90 The B7-1 inhibitor abatacept, approved for patients with rheumatoid arthritis, induces remission of proteinuria in both patients with post-transplant focalsegmental glomerulosclerosis and those with primary focal-segmental glomerulosclerosis. 91 Rare glomerulopathies involving podocyte integrins might also benefi t from this new indication for abatacept.
Monoclonal antibodies have shown remarkable effi cacy in several rare renal diseases. Eculizumab is a potent inhibitor of the terminal complement cascade (fi gure 3) and was fi rst approved for paroxysmal nocturnal haemoglobinuria. Mendelian inherited forms of atypical haemolytic uraemic syndrome have been associated with changes in proteins that regulate the alternative complement pathway. The resulting excessive complement activation leads to renal and systemic thrombotic microangiopathy, which leads to high mortality, rapid progression to end-stage renal disease, and a high risk of recurrence after kidney transplantation. 87 In studies, eculizumab caused complete disease remission in most patients and investigators reported notable recovery of renal function. 92 Its highly selective mechanism of action and positive benefi t-risk ratio also make eculizumab attractive for other complementmediated diseases. Unfortunately, the prohibitive cost of eculizumab is demonstrative of the challenges that face drug development in rare diseases. The discovery that recessive loss-of-function mutations in DGKE causes atypical haemolytic uraemic syndrome without activation of the complement system suggests that eculizumab will not be eff ective for this subset of patients. 93 Most AVPR2 and AQP2 mutations in nephrogenic diabetes insipidus result in retention of a normal protein within the endoplasmic reticulum (fi gure 3). Promising drugs include cell-permeable vasopressin-2 (V2) receptor antagonists and agonists that prevent the intracellular retention of mutated receptors in vitro. 26, 88 Of note, V2 receptor antagonists might produce diff erent eff ects depending on the various mutations. 94 In individuals with missense AVPR2 mutations, a non-peptide vasopressin-1a receptor antagonist had benefi cial eff ects on urine volume and osmolality within hours of administration. 95 Although the long-term effi cacy of this drug could not be tested (its clinical development was discontinued because of cytochrome P450 interaction) other pharmacological chaperones await further in-vivo testing. Chaperones might also become attractive for other diseases in which point mutations lead to defective folding and cellular traffi cking of otherwise intact membrane proteins (eg, uromodulin-associated kidney diseases). 78 Developments in this specialty rely on highthroughput compound screening systems to reproduce mutations in individual renal-cell types.
Health policies
A major objective for the inherited kidney disorders community is to design methods so that approaches developed at highly specialised and resourced tertiary care centres (which have access to patient cohorts and diagnostic and genetic information) can be adopted in less-resource-intensive settings (which cover most of the population). Investigators should devise practical ways to promote the adoption and implementation of clinically relevant genetic testing. Changes to the medical model in many countries-increased patient empowerment, more active roles for patient organisations, possibilities of crowd-sourcing, and creation of online communitieswill probably favour genetic interpretation on a personal level. Best practice guidelines for diagnosis and treatment of rare inherited kidney disorders are being established. 96 Equally important will be measures to ensure delivery and to support the eff ect of the genetic information on physicians, patients, and society. 30, 31 These eff orts are supported by numerous network and initiatives, and by organisations such as National Organisations of Rare Disorders (NORD) in the USA and Orphanet in Europe.
Research for rare diseases is expected to have important repercussions on public health policies. Measures to translate research insights into clinical benefi t include creation of centres of excellence with adequate diagnostic and therapeutic capabilities, genetic counselling, early detection by global or targeted public screening programmes, and facilitated approval of novel orphan drugs. 97 Insights from research into rare diseases could also be used to modify established public health measures through identifi cation of patients at particular risk. For instance, results of a study of children with idiopathic hypercalciuria identifi ed mutations in CYP24A1 gene coding for the vitamin D metabolising enzyme as the underlying pathology. 98 Subsequently, investigators also detected mutations in this gene in patients who developed severe hypercalcaemia after prophylactic bolus vitamin D administration, thereby identifying a subset of individuals intolerant to this public health measure.
Finally, we stress that patient organisations have a crucial role in closing of the gap between mechanistic understanding and the development of drugs for rare diseases.
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Patients work with physicians and researchers to share personal insights, provide biological samples, contact family members, and participate in clinical trials. Patient organisations can foster these activities and provide support to the community. Examples in rare kidney diseases include associations for cystic kidney disorders, primary hyperoxaluria, cystinosis, Lowe's syndrome, metabolic disorders, and so on. Coalitions of patient organisations have been important stakeholders in health policies, helping to pass the US Orphan Drug Act in 1983 and to establish the Framework Programme 7 research agenda in Europe.
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